Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBT (2016 - 2025)

Historic EBT for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to -$4.2 million.

  • Lisata Therapeutics' EBT rose 1381.34% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.2 million, marking a year-over-year increase of 1083.67%. This contributed to the annual value of -$20.8 million for FY2024, which is 1030.21% up from last year.
  • Latest data reveals that Lisata Therapeutics reported EBT of -$4.2 million as of Q3 2025, which was up 1381.34% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Lisata Therapeutics' EBT registered a high of -$4.2 million during Q3 2025, and its lowest value of -$6.4 million during Q2 2023.
  • For the 3-year period, Lisata Therapeutics' EBT averaged around -$5.3 million, with its median value being -$5.3 million (2023).
  • Over the last 5 years, Lisata Therapeutics' EBT had its largest YoY gain of 2065.44% in 2024, and its largest YoY loss of 19.4% in 2024.
  • Over the past 3 years, Lisata Therapeutics' EBT (Quarter) stood at -$5.4 million in 2023, then increased by 14.07% to -$4.6 million in 2024, then grew by 7.83% to -$4.2 million in 2025.
  • Its EBT was -$4.2 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$5.7 million in Q1 2025.